322 related articles for article (PubMed ID: 15767581)
1. Viable adenovirus vaccine prototypes: high-level production of a papillomavirus capsid antigen from the major late transcriptional unit.
Berg M; Difatta J; Hoiczyk E; Schlegel R; Ketner G
Proc Natl Acad Sci U S A; 2005 Mar; 102(12):4590-5. PubMed ID: 15767581
[TBL] [Abstract][Full Text] [Related]
2. Mutant canine oral papillomavirus L1 capsid proteins which form virus-like particles but lack native conformational epitopes.
Chen Y; Ghim SJ; Jenson AB; Schlegel R
J Gen Virol; 1998 Sep; 79 ( Pt 9)():2137-46. PubMed ID: 9747722
[TBL] [Abstract][Full Text] [Related]
3. Protection of beagle dogs from mucosal challenge with canine oral papillomavirus by immunization with recombinant adenoviruses expressing codon-optimized early genes.
Johnston KB; Monteiro JM; Schultz LD; Chen L; Wang F; Ausensi VA; Dell EC; Santos EB; Moore RA; Palker TJ; Stanley MA; Jansen KU
Virology; 2005 Jun; 336(2):208-18. PubMed ID: 15892962
[TBL] [Abstract][Full Text] [Related]
4. HPV16 L1 capsid protein expressed from viable adenovirus recombinants elicits neutralizing antibody in mice.
Berg M; Gambhira R; Siracusa M; Hoiczyk E; Roden R; Ketner G
Vaccine; 2007 Apr; 25(17):3501-10. PubMed ID: 16914239
[TBL] [Abstract][Full Text] [Related]
5. Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas.
Suzich JA; Ghim SJ; Palmer-Hill FJ; White WI; Tamura JK; Bell JA; Newsome JA; Jenson AB; Schlegel R
Proc Natl Acad Sci U S A; 1995 Dec; 92(25):11553-7. PubMed ID: 8524802
[TBL] [Abstract][Full Text] [Related]
6. Immunization with a pentameric L1 fusion protein protects against papillomavirus infection.
Yuan H; Estes PA; Chen Y; Newsome J; Olcese VA; Garcea RL; Schlegel R
J Virol; 2001 Sep; 75(17):7848-53. PubMed ID: 11483728
[TBL] [Abstract][Full Text] [Related]
7. Naturally occurring, nonregressing canine oral papillomavirus infection: host immunity, virus characterization, and experimental infection.
Nicholls PK; Klaunberg BA; Moore RA; Santos EB; Parry NR; Gough GW; Stanley MA
Virology; 1999 Dec; 265(2):365-74. PubMed ID: 10600607
[TBL] [Abstract][Full Text] [Related]
8. Intraepithelial DNA immunisation with a plasmid encoding a codon optimised COPV E1 gene sequence, but not the wild-type gene sequence completely protects against mucosal challenge with infectious COPV in beagles.
Moore RA; Santos EB; Nicholls PK; White KL; Anderson DM; Lloyd A; Topley P; Romanos M; Thomsen L; Parmar V; Walcott S; Gough GW; Stanley MA
Virology; 2002 Dec; 304(2):451-9. PubMed ID: 12504584
[TBL] [Abstract][Full Text] [Related]
9. Co-vaccination with adeno-associated virus vectors encoding human papillomavirus 16 L1 proteins and adenovirus encoding murine GM-CSF can elicit strong and prolonged neutralizing antibody.
Liu DW; Chang JL; Tsao YP; Huang CW; Kuo SW; Chen SL
Int J Cancer; 2005 Jan; 113(1):93-100. PubMed ID: 15386434
[TBL] [Abstract][Full Text] [Related]
10. A multimeric L2 vaccine for prevention of animal papillomavirus infections.
Jagu S; Malandro N; Kwak K; Yuan H; Schlegel R; Palmer KE; Huh WK; Campo MS; Roden RB
Virology; 2011 Nov; 420(1):43-50. PubMed ID: 21920572
[TBL] [Abstract][Full Text] [Related]
11. Production of human papillomavirus type 33 L1 major capsid protein and virus-like particles from Bacillus subtilis to develop a prophylactic vaccine against cervical cancer.
Baek JO; Seo JW; Kwon O; Park SM; Kim CH; Kim IH
Enzyme Microb Technol; 2012 Mar; 50(3):173-80. PubMed ID: 22305172
[TBL] [Abstract][Full Text] [Related]
12. Intra-epithelial vaccination with COPV L1 DNA by particle-mediated DNA delivery protects against mucosal challenge with infectious COPV in beagle dogs.
Stanley MA; Moore RA; Nicholls PK; Santos EB; Thomsen L; Parry N; Walcott S; Gough G
Vaccine; 2001 Apr; 19(20-22):2783-92. PubMed ID: 11282188
[TBL] [Abstract][Full Text] [Related]
13. Capsid display of a conserved human papillomavirus L2 peptide in the adenovirus 5 hexon protein: a candidate prophylactic hpv vaccine approach.
Wu WH; Alkutkar T; Karanam B; Roden RB; Ketner G; Ibeanu OA
Virol J; 2015 Sep; 12():140. PubMed ID: 26362430
[TBL] [Abstract][Full Text] [Related]
14. Cloning and Expression of L1 Protein Human Papillomavirus Type 31 Isolated from Iranian Patients in Escherichia coli.
Hajmohammadi S; Rassi H
Monoclon Antib Immunodiagn Immunother; 2016 Aug; 35(4):181-5. PubMed ID: 27244269
[TBL] [Abstract][Full Text] [Related]
15. Vaccine regimen for prevention of sexually transmitted infections with human papillomavirus type 16.
Kowalczyk DW; Wlazlo AP; Shane S; Ertl HC
Vaccine; 2001 May; 19(25-26):3583-90. PubMed ID: 11348726
[TBL] [Abstract][Full Text] [Related]
16. Expression of HPV-11 L1 protein in transgenic Arabidopsis thaliana and Nicotiana tabacum.
Kohl TO; Hitzeroth II; Christensen ND; Rybicki EP
BMC Biotechnol; 2007 Sep; 7():56. PubMed ID: 17850660
[TBL] [Abstract][Full Text] [Related]
17. Human papillomavirus vaccines.
Stanley MA
Rev Med Virol; 2006; 16(3):139-49. PubMed ID: 16710836
[TBL] [Abstract][Full Text] [Related]
18. VLP production in Leishmania tarentolae: A novel expression system for purification and assembly of HPV16 L1.
Bolhassani A; Shirbaghaee Z; Agi E; Davoudi N
Protein Expr Purif; 2015 Dec; 116():7-11. PubMed ID: 26304732
[TBL] [Abstract][Full Text] [Related]
19. Codon optimization of the human papillomavirus 11 (HPV 11) L1 gene leads to increased gene expression and formation of virus-like particles in mammalian epithelial cells.
Mossadegh N; Gissmann L; Müller M; Zentgraf H; Alonso A; Tomakidi P
Virology; 2004 Aug; 326(1):57-66. PubMed ID: 15262495
[TBL] [Abstract][Full Text] [Related]
20. The L1 major capsid protein of human papillomavirus type 16 variants affects yield of virus-like particles produced in an insect cell expression system.
Touze A; El Mehdaoui S; Sizaret PY; Mougin C; Muñoz N; Coursaget P
J Clin Microbiol; 1998 Jul; 36(7):2046-51. PubMed ID: 9650960
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
